Celladon Corp (CLDN) 16.45 $CLDN
Why Earnings Season Could Be Great for Celladon (CLDN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 7:55AM CST
Celladon has a favorable Zacks Rank and an ESP in positive territory, thus investors might want to consider this stock ahead of earnings
CLDN: 16.45 (-0.05)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 39.06 (+0.92), GPRO: 45.27 (-0.02), CLDN: 16.45 (-0.05), ZEN: 25.38 (+1.02), ASPX: 65.76 (+2.76), TNET: 36.49 (+0.76), NVRO: 43.70 (+0.57), OCUL: 31.25 (-0.01), RDUS: 50.37 (+0.63), ALDR: 26.06 (+0.18), IRMD: 14.61 (-0.35), KITE: 62.59 (+0.82), TUBE: 15.69 (+0.93), VBLT: 14.11 (+0.24)
Celladon Corporation to Present at the BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that the Company will provide a corporate update and overview at the BIO CEO & Investor Conference, being held at the Waldorf-Astoria hotel in New York City on February 9-10, 2015.
CLDN: 16.45 (-0.05)
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Jan 10, 1:07PM CST
Source: Flickr via Idaho National Laboratory. Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage...
BLUE: 90.70 (+0.93), DVAX: 16.96 (+0.66), HTGC: 15.49 (+0.04), NVAX: 8.80 (+0.40), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), CLDN: 16.45 (-0.05), GSK: 47.94 (+1.99)
Celladon Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Fri Jan 09, 7:06AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that on January 5, 2015 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 13,500 shares of common stock to two new employees.
CLDN: 16.45 (-0.05)
Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside
Stock Reversals - Seeking Alpha - Wed Jan 07, 4:10PM CST
We believe Celladon (NASDAQ: CLDN ) has the potential to be a wealth builder for early investors ahead of its April Phase 2b data release. The company has been increasing credit lines, setting up manufacturing agreements and running test batches ...
CLDN: 16.45 (-0.05)
These 3 Gold Stocks Climbed Over 11% Today
at The Street - Tue Jan 06, 5:06PM CST
Today's gold rally resulted in climbs for Kinross Gold Corporation (NYSE:KGC), Yamana Gold Inc. (NYSE:AUY) and AuRico Gold Inc. (NYSE:AUQ). CHC Grop Ltd. (NYSE:HELI), Celladon Corp. (NASDAQ:CLDN) an...
ECR: 7.29 (+0.12), KGC: 2.81 (-0.17), AUQ: 3.58 (-0.03), CLDN: 16.45 (-0.05), HELI: 2.11 (+0.03)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CERS: 5.53 (+0.08), QADB: 17.59 (+0.05), CTSO: 8.20 (+0.18), QADA: 20.36 (+0.14), CLDN: 16.45 (-0.05), GWGH: 6.64 (unch), HEES: 22.94 (+0.77), PEIX: 9.82 (+0.15), MTEX: 23.89 (+0.69), AREX: 8.15 (+0.27)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), HGG: 6.78 (+0.34), QADA: 20.36 (+0.14), CBMX: 1.83 (-0.16), CHOP: 0.87 (-0.01), CLDN: 16.45 (-0.05), MOC: 2.24 (+0.02), NDRM: 10.76 (+0.22), CALI: 1.35 (+0.06), GDP: 3.58 (+0.29), TNXP: 5.78 (-0.02), ICEL: 5.27 (+0.02), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), BBLU: 1.26 (+0.09), ATHX: 2.12 (unch), PEIX: 9.82 (+0.15), PGN: 2.88 (-0.07)
Celladon Corporation Conducts Initial Scale Up of Manufacturing Process for MYDICAR to Commercial Scale
GlobeNewswire - Mon Jan 05, 6:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has conducted initial scale up of its viral manufacturing process for MYDICAR (AAV1/SERCA2a) to commercial scale.
CLDN: 16.45 (-0.05)
Billionaires Are Gobbling Up These Stocks Right Now
George Budwell, The Motley Fool - Motley Fool - Tue Dec 30, 5:55AM CST
The investing public tends to take a special interest in the stocks billionaire investors are buying or selling, often copying their behavior in hopes of beating the broader market. According to recent 13F filings submitted to the SEC, we have...
ABT: 46.09 (+0.87), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), KITE: 62.59 (+0.82), PFE: 34.64 (-0.23), CLDN: 16.45 (-0.05), ABBV: 58.05 (+1.00)
Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble
at The Street - Mon Dec 29, 3:25PM CST
Sears Hometown and Outlet Stores Inc (NASDAQ:SHOS), Celladon Corp (NASDAQ:CLDN) and Repros Therapeutics Inc (NASDAQ:RPRX) are gaining this Monday. Gulf Coast Ultra Deep Royalty Trust (NASDAQ:GULTU),¿...
RIGP: 15.88 (+0.63), RPRX: 8.76 (+0.09), CLDN: 16.45 (-0.05), SSE: 5.23 (+0.22), SHOS: 12.86 (+0.47)
Celladon Corporation Added to NASDAQ Biotechnology Index
GlobeNewswire - Tue Dec 16, 7:06AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has been added to the NASDAQ Biotechnology Index, through the annual update that will become effective prior to market open on Monday, December 22, 2014.
CLDN: 16.45 (-0.05)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:09AM CST
Celladon Corporation stock fell nearly 9% last trading session, reversing its recent trend
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), CLDN: 16.45 (-0.05), AFFX: 11.45 (+0.02)
Why Earnings Season Could Be Great for Celladon (CLDN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 7:55AM CST
Celladon has a favorable Zacks Rank and an ESP in positive territory, thus investors might want to consider this stock ahead of earnings
CLDN: 16.45 (-0.05)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 39.06 (+0.92), GPRO: 45.27 (-0.02), CLDN: 16.45 (-0.05), ZEN: 25.38 (+1.02), ASPX: 65.76 (+2.76), TNET: 36.49 (+0.76), NVRO: 43.70 (+0.57), OCUL: 31.25 (-0.01), RDUS: 50.37 (+0.63), ALDR: 26.06 (+0.18), IRMD: 14.61 (-0.35), KITE: 62.59 (+0.82), TUBE: 15.69 (+0.93), VBLT: 14.11 (+0.24)
Celladon Corporation to Present at the BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that the Company will provide a corporate update and overview at the BIO CEO & Investor Conference, being held at the Waldorf-Astoria hotel in New York City on February 9-10, 2015.
CLDN: 16.45 (-0.05)
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Jan 10, 1:07PM CST
Source: Flickr via Idaho National Laboratory. Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage...
BLUE: 90.70 (+0.93), DVAX: 16.96 (+0.66), HTGC: 15.49 (+0.04), NVAX: 8.80 (+0.40), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), CLDN: 16.45 (-0.05), GSK: 47.94 (+1.99)
Celladon Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Fri Jan 09, 7:06AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that on January 5, 2015 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 13,500 shares of common stock to two new employees.
CLDN: 16.45 (-0.05)
Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside
Stock Reversals - Seeking Alpha - Wed Jan 07, 4:10PM CST
We believe Celladon (NASDAQ: CLDN ) has the potential to be a wealth builder for early investors ahead of its April Phase 2b data release. The company has been increasing credit lines, setting up manufacturing agreements and running test batches ...
CLDN: 16.45 (-0.05)
These 3 Gold Stocks Climbed Over 11% Today
at The Street - Tue Jan 06, 5:06PM CST
Today's gold rally resulted in climbs for Kinross Gold Corporation (NYSE:KGC), Yamana Gold Inc. (NYSE:AUY) and AuRico Gold Inc. (NYSE:AUQ). CHC Grop Ltd. (NYSE:HELI), Celladon Corp. (NASDAQ:CLDN) an...
ECR: 7.29 (+0.12), KGC: 2.81 (-0.17), AUQ: 3.58 (-0.03), CLDN: 16.45 (-0.05), HELI: 2.11 (+0.03)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CERS: 5.53 (+0.08), QADB: 17.59 (+0.05), CTSO: 8.20 (+0.18), QADA: 20.36 (+0.14), CLDN: 16.45 (-0.05), GWGH: 6.64 (unch), HEES: 22.94 (+0.77), PEIX: 9.82 (+0.15), MTEX: 23.89 (+0.69), AREX: 8.15 (+0.27)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), HGG: 6.78 (+0.34), QADA: 20.36 (+0.14), CBMX: 1.83 (-0.16), CHOP: 0.87 (-0.01), CLDN: 16.45 (-0.05), MOC: 2.24 (+0.02), NDRM: 10.76 (+0.22), CALI: 1.35 (+0.06), GDP: 3.58 (+0.29), TNXP: 5.78 (-0.02), ICEL: 5.27 (+0.02), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), BBLU: 1.26 (+0.09), ATHX: 2.12 (unch), PEIX: 9.82 (+0.15), PGN: 2.88 (-0.07)
Celladon Corporation Conducts Initial Scale Up of Manufacturing Process for MYDICAR to Commercial Scale
GlobeNewswire - Mon Jan 05, 6:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has conducted initial scale up of its viral manufacturing process for MYDICAR (AAV1/SERCA2a) to commercial scale.
CLDN: 16.45 (-0.05)
Billionaires Are Gobbling Up These Stocks Right Now
George Budwell, The Motley Fool - Motley Fool - Tue Dec 30, 5:55AM CST
The investing public tends to take a special interest in the stocks billionaire investors are buying or selling, often copying their behavior in hopes of beating the broader market. According to recent 13F filings submitted to the SEC, we have...
ABT: 46.09 (+0.87), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), KITE: 62.59 (+0.82), PFE: 34.64 (-0.23), CLDN: 16.45 (-0.05), ABBV: 58.05 (+1.00)
Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble
at The Street - Mon Dec 29, 3:25PM CST
Sears Hometown and Outlet Stores Inc (NASDAQ:SHOS), Celladon Corp (NASDAQ:CLDN) and Repros Therapeutics Inc (NASDAQ:RPRX) are gaining this Monday. Gulf Coast Ultra Deep Royalty Trust (NASDAQ:GULTU),¿...
RIGP: 15.88 (+0.63), RPRX: 8.76 (+0.09), CLDN: 16.45 (-0.05), SSE: 5.23 (+0.22), SHOS: 12.86 (+0.47)
Celladon Corporation Added to NASDAQ Biotechnology Index
GlobeNewswire - Tue Dec 16, 7:06AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has been added to the NASDAQ Biotechnology Index, through the annual update that will become effective prior to market open on Monday, December 22, 2014.
CLDN: 16.45 (-0.05)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:09AM CST
Celladon Corporation stock fell nearly 9% last trading session, reversing its recent trend
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), CLDN: 16.45 (-0.05), AFFX: 11.45 (+0.02)
